Stockwatch: Colors Of The Fall
This article was originally published in Scrip
Executive Summary
Something strange is happening in the stock market. What ended up as the best week of the year for the broad S&P 500 index was a down-week and month to date for the NASDAQ Biotechnology Index (NBI). This is not supposed to happen since the biotech sector is higher beta, meaning that if the broad equity index finishes the week up, the NBI should finish the week up more.
You may also be interested in...
Stockwatch: Pricing Delusions Of Blockbuster Proportions
Sales expectations for the products of companies like Acadia, BTG, Keryx and probably Sarepta remain too high, despite the bursting of the last biotech bubble. Aggressive price increases have traditionally been one way to inch closer to those expectations but that door has closed.
Stock Watch: Is Johnson & Johnson Edging Away From Pharma?
J&J’s Medtech division outshone pharma while recently launched innovative products contributed minimally: it is to be hoped investors’ reactions to the first set of big pharma Q1 results will not set the tempo for earnings season.
Stock Watch: Risk And The Pharmaceutical Discount Rate
In contrast to the SEC’s view that public companies’ regulatory filings give investors all the information needed to make an investment decision, the discount rate used to value a company may not reflect all its risks.